


Prenatal Diagnosis of Thalassaemia

KY Leung, MBBS, FRCOG, FHKAM(O&G); KB Cheong, MBBS, MMedSc; MHY Tang, MBBS, FRCOG, FHKAM (O&G); Vivian Chan, MSc, PhD (Lond), DIC, FACB, FRCPath, HonFRCP (Lond), HonFHKCP



The two major types of thalassaemias are transfusion-dependent β -thalassaemia major and homozygous α^0 -thalassaemia

INTRODUCTION

Thalassaemias are a major public health problem in many parts of the world.¹ They are a family of inherited disorders of haemoglobin synthesis characterized by a reduced output of one or other of the globin chains of adult haemoglobin. The two main disorders are transfusion-dependent β -thalassaemia major and homozygous α^0 -thalassaemia. Although fetuses affected by homozygous α^0 -thalassaemia usually die in-utero or in the early neonatal period, prenatal diagnosis is still justified because of maternal morbidities, including pre-eclampsia, haemorrhage, the adverse psychological impact of carrying a hydrops fetalis to term only to result in a still-birth, and, occasionally,

death.² Homozygous haemoglobin E (HbE) is associated with mild anaemia only, but coinheritance of β -thalassaemia may result in a transfusion-dependent state. The coinheritance of the sickle-cell gene and β -thalassaemia produces a disease that is similar to sickle-cell anaemia. Thalassaemia is an autosomal recessive disorder, and if both the mother and father carry the same thalassaemia trait, their offspring will have a 1 in 4 chance of having thalassaemia major. The prevalence of different types of thalassaemia trait is up to 16% in Cypriot populations; 3% to 14% in Chinese and Thai populations; 3% to 8% in Indian, Pakistani and Bangladeshi populations; 0.9% in black Caribbean and African populations; and 0.1% in northern Europeans.³⁻⁵

Prenatal screening has been introduced worldwide to prevent severe thalassaemias,⁶⁻⁸ and has shown to be cost-effective in many places including the United Kingdom, Quebec, Israel and Hong Kong.⁹⁻¹³ The introduction of a preventive programme has resulted in a marked decline in the number of newborns with β -thalassaemia major.¹⁴ The choice of screening strategy used depends on the ethnic origin of the local population, as the latter has its own characteristic spectrum of haemoglobin variants and thalassaemia mutations. Conventionally, prenatal diagnosis is performed using amniocentesis or chorionic villus sampling (CVS) followed by DNA analysis. Compared to the original gene mapping method, recently-developed polymerase chain reaction (PCR) methods and arrays are simpler, faster and less expensive, but PCR methods are associated with specific diagnostic pitfalls.¹⁵ A noninvasive approach using serial ultrasound examinations has been shown to effectively reduce the need for an invasive test in pregnancies unaffected by homozygous α^0 -thalassaemia. Other methods, including assessment of maternal serum markers, maternal plasma fetal erythrocytes, maternal plasma fetal DNA, and three-dimensional ultrasound examination, have been investigated. The aim of the present review article is to provide an update on the clinical aspects of prenatal screening and diagnosis of severe thalassaemias.

ANTENATAL SCREENING

Universal antenatal screening for thalassaemia has been advocated for populations with a high prevalence of asymptomatic thalassaemia trait. With population migration, thalassaemias are no longer regionally specific. Selective prenatal screening tests have been offered to at-risk couples because of their ethnic origin. Web-based population and genetic information on thalassaemia mutations and variants is available for easy reference.¹⁶

There is no universal screening policy which can suit all countries because of the heterogeneity of thalassaemias and the association with haemoglobin variants in different ethnic groups. For populations with thalassaemias as the major health problem, measurement of maternal mean corpuscular volume (MCV) or mean corpuscular haemoglobin (MCH) has been adopted as a screening parameter.¹⁷ Both MCV and MCH are useful as screening for α - and β -thalassaemia traits. The choice depends on the familiarity of the local laboratory with the measurement of each parameter, and whether storage of blood before testing for MCV/MCH is required. MCH has the theoretical advantage over MCV because it is more stable over time. For populations with a high prevalence of sickle cell and β -thalassaemia traits, haemoglobin electrophoresis as well as MCV/MCH should be performed for screening because the latter is not useful for detecting sickle cell trait.

Different MCV cutoffs between 76 fL and 82 fL have been used. By genotyping archived samples from schoolchildren with an MCV up to 85 fL, it has been shown that a MCV cutoff of 80 fL or MCH cutoff of 27 pg could detect

all Southeast Asia (SEA) deletion carriers and β -thalassaemia carriers.¹⁸ With MCH, 27 pg seems to be the most acceptable cutoff.

Prenatal screening for thalassaemia has resulted in a marked decline in the number of affected newborns

If maternal MCV or MCH is found to be low, checking the partner's blood will be required. If the partner's MCV or MCH is also low, α^0 -thalassaemia trait, β -thalassaemia trait or iron deficiency need to be excluded in both partners.¹⁹ Laboratory tests to look for the presence of HbH inclusion bodies and elevation in HbA2 should be performed, as should an iron study. The presence of HbH-inclusive inclusion bodies and elevation of HbA2 (>3.5%) are diagnostic of α^0 -thalassaemia trait and β -thalassaemia, respectively. Although normal A2 β -thalassaemia exists, it is extremely rare. If HbA2 level is normal, HbH inclusion bodies are absent, and iron deficiency is detected, women should be treated with iron therapy first, followed by repeat MCV or MCH 4 weeks later, before further investigations on their thalassaemia status.¹⁹ An increase in their Hb by 1 g/dL and an increase in MCV after iron therapy for 4 weeks can be expected. In some ethnic groups such as Cypriots and Sardinians, the possibility of $\delta\beta$ -thalassaemia should be suspected in women with low MCV/MCH who have normal HbA2. $\delta\beta$ -thalassaemia and the deletion types of

hereditary persistence of fetal haemoglobin (HPFH) are characterized by an elevated level of HbF (5%-30%) in heterozygotes.²⁰

Couples with confirmed or suspected thalassaemia traits are preferably counselled by specialists in maternal-fetal medicine or specialists with an understanding of prenatal diagnosis of thalassaemias. DNA analysis will be performed to confirm suspected cases. In the presence of a low MCV and a normal iron status, absence of HbH inclusion bodies does not necessarily exclude α -thalassaemia, and DNA analysis is required to detect α -thalassaemia trait. Couples carrying α^0 -thalassaemia or β -thalassaemia minor have a 1 in 4 chance of having infants with homozygous α^0 -thalassaemia or β -thalassaemia major, respectively. For couples with discordant thalassaemia traits, their fetus will not be at risk of serious thalassaemia unless one parent who carries β -thalassaemia trait also has coinheritance of α^0 -thalassaemia. In regions with a high prevalence of both α - and β -thalassaemia, up to 7% of β -thalassaemia carriers are compound α - and β -thalassaemia heterozygotes,²¹ and ζ -mapping should thus be performed to exclude α -thalassaemia. If one parent has β -thalassaemia trait and the other has E-thalassaemia trait, their fetus will have a 1 in 4 risk of being compound heterozygous for β - and E-thalassaemia traits, which can be transfusion-dependent in the more severe phenotype.

Early screening allows time for workup and counselling for couples who are at risk. In case termination of pregnancy needs to be considered, timely diagnosis of thalassaemia major in the fetus is desirable. For populations with a high prevalence of α -thalassaemia

carriers, antenatal screening should be offered to all pregnant women regardless of gestational age, in view of maternal risks including pre-eclampsia and postpartum haemorrhage.

Education of healthcare professionals,²² information for couples and informed consent are required before screening. Information for couples may be provided through pamphlets, videos, websites or explanation in person. At-risk couples must be counselled on the maternal risks associated with affected pregnancies, together with the prognosis, available support and treatment for affected infants. They also need to be informed of the available invasive and noninvasive prenatal tests, risk of sampling, limitation and accuracy of prenatal tests, screening workflow, and the need for confirmation testing at delivery.

Prenatal screening for thalassaemia usually includes the measurement of maternal MCV/MCH with or without haemoglobin electrophoresis

Screening Pitfalls

If Hb electrophoresis is not performed as part of the initial screening, there is a possibility of missing some sickle cell carriers or HbE carriers whose MCVs are above 80 fL.²³ As a result, sickle cell disease (HbS/ β -thalassaemia) or β -thalassaemia syndrome (β -thalassaemia/

HbE) will be missed if the spouse carries β -thalassaemia trait. Whether Hb electrophoresis should be performed as part of the routine screening depends on the prevalence of HbE and sickle cell trait in a local population and on resources. In Hong Kong, Hb electrophoresis is not performed routinely because HbS is not found in the Chinese population.¹³

When iron deficiency is accompanied by a normal HbA2 level and an absence of HbH inclusion bodies, the approach of giving iron therapy for 4 weeks and then repeating MCV measurement before performing further investigations on thalassaemia status may lead to a delay in the prenatal diagnosis of both α - and β -thalassaemia. There is a possibility of concomitant thalassaemia trait and iron deficiency because in the presence of iron deficiency, HbA2 production may be depressed,²⁴ and the brilliant cresyl blue preparation used for the detection of HbH inclusion bodies may be affected. Either DNA analysis to exclude the possibility of α^0 -thalassaemia or serial ultrasound examinations to look for features of homozygous α^0 -thalassaemia, as described below, should be performed.

The above antenatal thalassaemia screening programmes are not aimed at couples who are at risk of having children with HbH disease. In α^+ -thalassaemia carriers (with single α -globin gene deletion or nondeletion α -globin gene mutation such as Hb Constant Spring), MCV can lie between 80 fL and 85 fL, and Hb electrophoresis gives normal results. The couple will have a chance



There is no universal screening policy which can suit all countries because of the heterogeneity of thalassaemias and the association with haemoglobin variants in different ethnic groups.

of having a child with HbH disease if the spouse carries α^0 -thalassaemia. However, prenatal diagnosis of HbH disease is usually not indicated because the affected individual is not transfusion-dependent and can enjoy a normal life. Rare cases of HbH hydrops fetalis have been reported.^{25,26} It is therefore necessary to determine the type of nondeletion α^+ -thalassaemia mutation of the parent.

In the presence of a low MCV and a normal iron status, absence of HbH inclusion bodies does not necessarily exclude α -thalassaemia



For couples with α^0 -thalassaemia, serial ultrasound examinations by experienced personnel can reduce the need for invasive testing.

PRENATAL DIAGNOSIS

When at-risk couples are identified, counseling and prenatal testing should be carried out by personnel and laboratories with experience in prenatal diagnosis.¹⁷

Prenatal Diagnosis of β -thalassaemia Major

As the type of DNA mutations present in each individual varies, it is important to know the ethnic origin of each partner and allow some time for the laboratory to identify the mutation. A thalassaemia (thal) array has been designed to speed up this process.²⁷ After identification of the parental mutations, the fetal diagnosis

is often accomplished by an invasive procedure (chorionic villus sampling [CVS] or amniocentesis), followed by DNA analysis. Occasionally, the mutations cannot be identified, and one may need to resort to cordocentesis and globin chain assay for prenatal diagnosis.²⁸ However, cordocentesis is associated with a 2% risk of miscarriage.²⁹

To avoid an invasive procedure, examination of the circulatory fetal DNA in maternal plasma for mutant paternal allele has been investigated. If paternal mutation is different from maternal mutation and the former is absent

from maternal plasma, it will be inferred that the fetus has not inherited the mutant paternal allele, and β -thalassaemia major can be excluded. However, if paternal mutation is present in the maternal plasma, an invasive procedure will still be needed because whether the fetus has inherited the maternal mutation cannot be determined from examination of the maternal plasma.^{30,31} However, there are several technical challenges, including failure to isolate or extract fetal DNA from maternal plasma, or PCR allele dropout.³¹ The use of advanced techniques such as single allele base extension reaction and Mass ARRAY system may be helpful.³¹ Further studies are needed before this noninvasive approach can be used clinically.

Prenatal diagnosis is usually performed by CVS or amniocentesis, followed by DNA analysis

Prenatal Diagnosis of Homozygous α^0 -thalassaemia

Homozygous α^0 -thalassaemia can be accurately diagnosed by DNA study of cells obtained from CVS or amniocentesis.³² With the use of quantitative PCR assay, a report can be rapidly available within 1 or 2 days after amniocentesis or CVS.³³ In areas where DNA diagnosis is not easily available, the more invasive technique of cordocentesis, followed by haemoglobin analysis, is an alternative. In affected fetuses, fetal anaemia is found, and haemoglobin electrophoresis shows the presence of Hb Bart's and Hb Portland.

With experienced personnel and a good ultrasound machine, serial ultrasound examinations at 12 to 15, 18 to 20, and 30 weeks' gestation can effectively reduce the need for invasive testing in the majority of unaffected pregnancies.^{19,34,35} If there is fetal cardiomegaly (cardiothoracic ratio [CTR] ≥ 0.50 , 0.52, and 0.59 at 12 to 15, 18 and 30 weeks' gestation, respectively), and/or placentalomegaly (placental thickness >18 mm at 12 weeks' gestation), CVS or amniocentesis for fetal DNA analysis should be performed for confirmation of α^0 -thalassaemia major.¹⁹ On the other hand, if ultrasound examinations are normal, an invasive procedure can

be omitted. This approach is applicable in singleton as well as twin pregnancies,³⁶ and can be used to confirm normality in pregnancies conceived after preimplantation genetic diagnosis.³⁷

Ultrasound Diagnostic Pitfalls

There are several limitations of the non-invasive approach of using serial ultrasound examinations. Firstly, measurement of placental thickness may be inaccurate if the placenta is adjacent to a focal myometrial contraction, or located in the fundus or lateral uterine wall. In an affected pregnancy, the placenta can be large but its thickness can be normal.³⁸ Secondly, the predictive values of fetal CTR decrease with gestational age.¹⁹ In advanced gestation, hydropic signs, including ascites and pleural effusion, are more apparent than cardiomegaly in affected pregnancies.¹⁹ Measurement of fetal middle cerebral artery peak systolic velocity may be useful.^{20,39} Thirdly, the false-positive rate of this noninvasive approach is about 3% because disorders such as intrauterine growth restriction, congenital heart disease,¹⁹ and HbH disease can present with cardiomegaly and/or placentomegaly. An invasive test is needed to confirm the diagnosis of an affected fetus. Fourthly, this noninvasive approach demands accurate measurement of the fetal CTR. Adequate training and subsequent quality control are essential. When the image quality of the fetal heart at 12 weeks' gestation is suboptimal – even with the use of a transvaginal scan – rescanning in 2 to 3 weeks would be a reasonable option if the mother still prefers ultrasound monitoring to invasive testing.¹⁹ The risk of delaying

the diagnosis of an affected pregnancy until the second trimester and the disadvantages of terminating an affected pregnancy in the second trimester should be balanced against the risk (1%) of invasive testing.

Other noninvasive methods have been investigated. If a woman opts for first trimester combined Down's syndrome screening, normal maternal serum-free β human chorionic gonadotropin (β -hCG) and pregnancy-associated plasma protein A (PAPP-A) at 11 to 14 weeks of gestation is a reassuring sign of normality for fetuses at risk of homozygous α^0 -thalassaemia. A high level of free β -hCG, however, is not predictive of affected fetuses.⁴⁰ Immunofluorescence staining of fetal erythrocytes in maternal blood is a potentially useful but labour-intensive non-invasive technique in the first trimester.⁴¹ In affected pregnancies, positive staining with fluorescence-labelled monoclonal anti-zeta (but not with anti-alpha) globin antibodies can identify fetal non-nucleated red blood cells. More recently, it has become feasible to provide a potentially rapid noninvasive test using real-time quantitative seminested PCR,⁴² or a multiplex quantitative fluorescent PCR (QF-PCR) test.⁴³ The maternal blood is examined using simultaneous detection of homozygous α^0 -thalassaemia by the absence of both microsatellite markers located within breakpoints of the SEA deletion, and exclusion of maternal contamination by the absence of noninherited maternal alleles.⁴⁴

Laboratory Diagnostic Pitfalls

Most of the errors in diagnosis result from maternal contamination, or nonpaternity or technical problems of DNA analysis.⁴⁴ If prenatal diagnosis of α^0 -thalassaemia

is made solely by PCR assay on fetal DNA, errors in diagnosis may occur due to failure of the PCR assay to generate a specific DNA fragment.⁴⁵ Maternal contamination can be reduced by using careful invasive techniques, dissecting maternal decidua from the fetal trophoblast, and reducing the number of amplification cycles to 25.⁴⁶ If the fetal diagnosis is identical to the maternal genotype, checking maternal contamination by DNA polymorphism analysis to avoid the possibility of misdiagnosis will be required.

CONCLUSIONS

Prenatal screening for thalassaemia usually includes the measurement of MCV/MCH with or without Hb electrophoresis, depending on the ethnic origin of the local population. When at-risk couples are identified, counselling and prenatal testing should be carried out by personnel and laboratories with experience in prenatal diagnosis. Prenatal diagnosis is usually performed by CVS or amniocentesis, followed by DNA analysis. For couples who have α^0 -thalassaemia, with experienced personnel and good ultrasound machines, serial ultrasound examination can be offered, reserving invasive diagnosis for those showing ultrasound features of an affected pregnancy.

About the Authors

Dr Leung is Consultant and Dr Cheong is a Ph student at the Department of Obstetrics and Gynaecology, University of Hong Kong, Queen Mary Hospital; Dr Tang is Consultant at the Prenatal Diagnostic and Counselling Department, Tsan Yuk Hospital; Professor Chan is Professor at the Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China.
E-mail: leungky1@ha.org.hk

REFERENCES

1. World Health Organisation. Report on the community control of hereditary anemia. Memorandum from WHO meeting, Bull WHO 1982;61:63-80.
2. Liang ST, Wong VC, So WW, Ma HK, Chan V, Todd D. Homozygous alpha-thalassaemia: clinical presentation and management. A review of 46 cases. Br J Obstet gynaecol 1985;92:680-684.
3. Health Technology Assessment. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research (Davies). 2000;4:1-99.
4. Fucharoen S, Winichagoon P. Haemoglobinopathies in Southeast Asia. Hemoglobin 1987;11:65-88.
5. Xu XM, YQ Zhou, GX Luo, et al. The prevalence and spectrum of α - and β -thalassaemia in Guangdong Province: implications for the future health burden and population screening. J Clin Pathol 2004;7:517-522.
6. Kan YW, Nathan DG, Cividali G, Frigoletto F. Intrauterine diagnosis of thalassaemia. Ann N Y Acad Sci 1974;232:145-151.
7. Wong V, Ma HK, Todd D, Golbus MS, Dozy AM, Kan YW. Diagnosis of homozygous alpha-thalassaemia in cultured amniotic-fluid fibroblasts. N Engl J Med 1978;298:669-670.
8. Beris P, Darbellay R, Extermann P. Prevention of β -thalassaemia major and Hb Bart's Hydrops Fetalis Syndrome. Seminars in Hematology 1995;32:244-261.
9. Cronin EK, Normand C, Henthorn JS, Graham V, Davies SC. Organisation and cost-effectiveness of antenatal haemoglobinopathy screening and follow up in a community-based programme. Br J Obstet Gynaecol 2000;107:486-491.
10. Ginsberg G, Tulchinsky T, Filon D, Goldfarb A, Abramov L, Rachmilevitz B. Cost-benefit analysis of a national thalassaemia prevention programme. J Med Screen 1998;5:120-126.
11. Ostrowsky JT, Lippman A, Scriver CR. Cost-benefit analysis of α thalassaemia disease prevention program. Am J Public Health 1985;75:732-736.
12. Leung KY, Lee CP, Tang MHY, Chan HY, Chan V. Prenatal diagnosis of alpha-thalassaemia in a twin pregnancy. Ultrasound Obstet Gynecol 2005;25:201-202.
13. Chan V. Prenatal Diagnosis of alpha and beta thalassaemias and haemophilia A: experience in Hong Kong. Clin Biochem 1990;23:79-84.
14. Cao A, Rosatelli MC, Munni G, Galanello R. Thalassaemia – The knowledge database of the Swedish National Board of Health and Welfare on rare diseases. Screening for thalassaemia, a model of success. Obstet Gynecol Clin North Am 2002;29:305-328.
15. Rosatelli MC, Tuveri T, Scalas MT, et al. Molecular screening and fetal diagnosis of β -thalassaemia in the Italian population. Hum Genet 1992;89:585-589.
16. Giardina B, van Baal S, Kaimakis P, et al. HbVar database of human hemoglobin variants and thalassaemia mutations. Hum Mutat 2007 update;28:206.
17. Leung KY, Lee CP, Tang MHY, et al. Cost-effectiveness of prenatal screening for thalassaemia in Hong Kong. Prenat Diagn 2004;24:899-907.
18. Ma ESK, Chan AYY, Ha SY, Lau YL, Chan LC. Thalassaemia screening based on red cell indices in the Chinese. Haematologica 2001;86:1286-1287.
19. Leung KY, Liao C, Li QM, et al. A new strategy for prenatal diagnosis of homozygous alpha-thalassaemia. Ultrasound Obstet Gynecol 2006;28:173-177.
20. Panyasai S, Fucharoen S, Surapot S, Fucharoen G, Sanchaisuriya K. Molecular basis and hematologic characterization of $\delta\beta$ -thalassaemia and hereditary persistence of fetal haemoglobin in Thailand. Haematologica 2004;89:777-781.
21. Lam YH, Ghosh A, Tang MHY, Lee CP, Sin SY. Early ultrasound prediction of pregnancies affected by homozygous α -thalassaemia-1. Prenat Diagn 1997;17:327-332.
22. Antenatal and newborn screening programme from the NHS Sickle Cell and Thalassaemia Screening Programme. Available from <http://www.sickleandthal.org.uk/antenatal.htm>. Accessed [1 October 2007].
23. Chan LC, Ma SK, Chan AYY, et al. Should we screen for globin gene mutations in blood samples with mean corpuscular volume (MCV) greater than 80fl in areas with a high prevalence of thalassaemia. J Clin Pathology 2001;54:317-320.
24. Fleming AF, Lynch W. Beta-thalassaemia minor during pregnancy with particular reference to iron status. Br J Obstet Gynaecol 1969;76:451-455.
25. Chan V, Chan TK, Liang ST, Ghosh A, Kan YW, Todd D. Hydrops fetalis due to an unusual form of Hb H disease. Blood 1985;66:224-228.
26. Chan V, Chan VW, Tang M, Lau K, Todd D, Chan TK. Molecular defects in Hb H hydrops fetalis. Br J Haematol 1997;96:224-228.
27. Chan K, Wong MS, Chan TK, Chan V. A thalassaemia array for Southeast Asia. Br J Haematol 2004;124:232-239.
28. Boussion M, Loukopoulos. Prenatal diagnosis of thalassaemia major and of haemoglobin S syndromes by protein methods: globin chain separation by chromatography on CMC. In Prenatal Diagnosis of Thalassaemia and Other Haemoglobinopathies. Edited by Loukopoulos D. CRC Press; 1988.
29. Tongsong T, Wanapirak C, Kunavikattikul C, et al. Cordocentesis at 16-24 weeks of gestation: experience of 1,320 cases. Prenat Diagn 2000;20:224-228.
30. Chiu WKK, Lau TK, Leung TN, Chow KCK, Chui DHK, Lo YMD. Prenatal exclusion of thalassaemia major by examination of maternal plasma. Lancet 2002;360:998-1000.
31. Ding C, Chiu RWK, Lau TK, et al. MS analysis of single-nucleotide differences in circulating nucleic acids: Application to noninvasive prenatal diagnosis. PNAS 2004;101:10762-10767.
32. Chan V, Ghosh A, Chan TK, Wong V, Todd D. Prenatal diagnosis of homozygous alpha thalassaemia by direct DNA analysis of uncultured amniotic fluid cells. Br Med J (Clin Res Ed) 1984;288:1327-1379.
33. Chan V, Yip B, Lam YH, Tse HY, Wong HS, Chan TK. Quantitative polymerase chain reaction for the rapid prenatal diagnosis of homozygous alpha-thalassaemia (Hb Bart's hydrops fetalis). Br J Haematol 2001;115:341-346.
34. Lam YH, Tang MHY, Lee CP, Tse HY. Prenatal ultrasonographic prediction of homozygous type 1 alpha-thalassaemia at 12-13 weeks of gestation. Am J Obstet Gynecol 1999;180:148-150.
35. Lam YH, Ghosh A, Tang MHY, Lee CP, Sin SY. Early ultrasound prediction of pregnancies affected by homozygous α -thalassaemia-1. Prenat Diagn 1997;17:327-332.
36. Leung KY, Lee CP, Tang MHY, Chan HY, Chan V. Prenatal diagnosis of alpha-thalassaemia in a twin pregnancy. Ultrasound Obstet Gynecol 2005;25:201-202.
37. Chan V, Ng EH, Yam I, Yeung WS, Ho PC, Chan TK. Experience in preimplantation genetic diagnosis for exclusion of homozygous alpha degrees thalassaemia. Prenat Diagn 2006;26:1029-1036.
38. Ghosh A, Tang MHY, Lam YH, Fung E, Chan V. Ultrasound measurement of placental thickness to detect pregnancies affected by homozygous α -thalassaemia-1. Lancet 1994;344:988-989.
39. Leung WC, Oepkes D, Seaward G, Ryan G. Serial sonographic findings of four fetuses with homozygous alpha-thalassaemia-1 from 21 weeks onwards. Ultrasound Obstet Gynecol 2002;19:56-59.
40. Ong CY, Lee CP, Leung KY, Lau E, Tang MHY. Human chorionic gonadotropin and plasma protein-A in alpha θ -thalassaemia pregnancies. Obstet Gynecol 2006;108:651-655.
41. Lau ET, Kwok YK, Luo HY, et al. Simple non-invasive prenatal detection of Hb Bart's disease by analysis of fetal erythrocytes in maternal blood. Prenat Diagn 2005;25:123-128.
42. Tungwiwat W, Fucharoen S, Fucharoen G, Ratanasiri T, Sanchaisuriya K. Development and application of a real-time quantitative PCR for prenatal detection of fetal alpha(0)-thalassaemia from maternal plasma. Ann N Y Acad Sci 2006;1075:103-107.
43. Ho SSY, Chong SS, Koay ESC, et al. Microsatellite markers within α -SEA breakpoints for prenatal diagnosis of Hb Bart's hydrops fetalis. Clinical Chemistry 2007;53:73-179.
44. Weatherall DJ. The thalassaemias. BMJ 1997;314:1675.
45. Ko TM, Tseng LH, Hwa HL, et al. Misdiagnosis of homozygous alpha-thalassaemia 1 may occur if polymerase chain reaction alone is used in prenatal diagnosis. Prenat Diagn 1997;17:505-509.
46. Rosatelli MC, Tuveri T, Scalas MT et al. Molecular screening and fetal diagnosis of β -thalassaemia in the Italian population. Hum Genet 1992;89:585-589.

Share With us Your Interesting CASES

JPOG welcomes case reports. Write to us if you have a case (or several cases) that

- has educational value;
- represents unusual aspects of common medical conditions; or
- suggests new solutions or perspectives upon clinically relevant issues.

The report should include a review of published relevant cases, a detailed description of the case, a discussion of why the case is unique and adds to the literature, and implications for subsequent developments in clinical practice.

For more information, please refer to the Instructions for Authors on our website www.jpog.com, or contact us at enquiry@jpog.com



Learning is a lifelong business.

Read the Continuing Medical Education article in this issue, and test your understanding by answering the following questions.

Answers are shown at the bottom of this page. We hope you enjoy learning with *JPOG*.

CME Article:

Prenatal Diagnosis of Thalassaemia

Answer True or False to the questions below.

	True	False
1. Measurement of maternal mean corpuscular volume (MCV) or mean corpuscular haemoglobin (MCH) is useful for prenatal screening for thalassaemia.	<input type="radio"/>	<input type="radio"/>
2. A normal haemoglobin pattern can exclude the possibility of α -thalassaemia.	<input type="radio"/>	<input type="radio"/>
3. If one parent carries β -thalassaemia trait while the other carries α -thalassaemia, their fetus will not be at risk for serious thalassaemia unless the parent who carries β -thalassaemia trait has coinheritance of α -thalassaemia.	<input type="radio"/>	<input type="radio"/>
4. If both the father and the mother carry haemoglobin E trait, their fetus will be at risk of severe thalassaemia.	<input type="radio"/>	<input type="radio"/>
5. In the presence of iron deficiency, the measurement of haemoglobin A2 production and detection of haemoglobin H inclusion bodies may be affected.	<input type="radio"/>	<input type="radio"/>
6. In the prenatal diagnosis of β -thalassaemia major, it is important to know the ethnic origin of each partner.	<input type="radio"/>	<input type="radio"/>
7. In the prenatal diagnosis of homozygous α^0 -thalassaemia, with the use of quantitative polymerase chain reaction assay, a report can be rapidly available within 1 or 2 days after amniocentesis or chorionic villus sampling.	<input type="radio"/>	<input type="radio"/>
8. Serial prenatal ultrasound examinations can effectively reduce the need for invasive testing in the majority of pregnancies unaffected by homozygous α^0 -thalassaemia.	<input type="radio"/>	<input type="radio"/>
9. Placental thickness is the most useful ultrasonographic parameter in the prediction of pregnancies affected by homozygous α^0 -thalassaemia.	<input type="radio"/>	<input type="radio"/>
10. In the prenatal diagnosis of thalassaemia, maternal contamination should be suspected if the fetal diagnosis is identical to the maternal genotype.	<input type="radio"/>	<input type="radio"/>

1 2 3 4 5 6 7 8 9 10

ANSWERS